How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,087 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Progestogen-only Injectable contraception

Effectiveness Unit This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. Your download should start automatically. If not . Document types Thinking about taking a qualification? Registration is now quick

2014 Faculty of Sexual & Reproductive Healthcare

123. Depot Medroxyprogesterone Acetate and Bone Effects

medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density. Contraception 2008;77:239–48. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010;81:281–91. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate (...) . The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008;78:459–64. Pfizer Inc. Depo-provera CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use: highlights of prescribing information. New York (NY): Pfizer; 2012. Available at: . Retrieved February 12, 2014. Hatcher RA, Trussell J, Nelson AL, Cates WJ, Kowal D, Policar MS. Contraceptive technology. 20th ed. New York (NY): Ardent Media; 2012. Cundy T, Ames R

2014 American College of Obstetricians and Gynecologists

124. St Johns Wort and Hormonal Contraception

-druginteractions.org St John’s Wort and Hormonal Contraception 2014 Reference List (1) Faculty of Sexual & Reproductive Health Care. Drug Interactions with Hormonal Contraception. http://www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf. 2011. (2) Pfizer Limited. Sayana Press:Summary of Product Characteristics. 2013. http://www.medicines.org.uk/emc/medicine/27798/SPC/SAYANA+PRESS+1 04+mg+0.65+ml+suspension+for+injection (3) Pfizer Limited. Depo-Provera 150mg / ml injection. 2012. http (...) ://www.medicines.org.uk/emc/medicine/11121/SPC/Depo- Provera+150mg+ml+Injection/ (accessed 19/03/14) (4) Watts DH, Park JG, Cohn SE, Yu SHJ, Stek A, Clax PA, et al. Safety and Tolerability of DMPA among HIV infected women on antireteroviral therapy. Contrcaeption 2008;72((2)):84-90. (5) Nanda K, Amaral E, Hays M, Viscola MAM, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertility and Sterility 2008;90(4):965-71.

2014 Faculty of Sexual & Reproductive Healthcare

125. Antigone (desogestrel) - Contraception

and its generics and 3 hours for MICROVAL. HAS - Medical, Economic and Public Health Assessment Division 6/12 6.1.2 Other progestogen contraceptives For information, progestogen contraceptives are used parenterally: NEXPLANON 68 mg, implant for subdermal use (etonogestrel): - indication: "Contraception. The safety and efficacy have been established in women between 18 and 40 years of age." - the implant may be left in place for 3 years, - reimbursable proprietary medicinal product. DEPO PROVERA

2014 Haute Autorite de sante

126. Osteoporosis: Prevention and Treatment

. Medications with Risk for Bone Loss or Fracture Definite risk Immunosuppressants • Glucorticoids (systemic >> inhaled a , intranasal, topical, others) • Cyclosporine [Gengraf®, Neoral®, Sandimmune®] • Tacrolimus [Prograf®] • Mycophenolate mofetil [CellCept®] Hormonal and antihormonal agents • Medroxyprogesterone acetate [Depo-Provera®] b • Tamoxifen, before menopause • Aromatase inhibitors (anastrozole/Arimidex®, letrozole/Femara®) • GnRH analogs (leuprolide/Lupron®, goserelin/Zoladex®

2013 University of Michigan Health System

127. Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

be able to read, comprehend, and write at a level sufficient to complete study related materials. Female subjects: Women of childbearing potential (WOCBP) must use an effective form of birth control (confirmed by the Investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intra-uterine device (IUD) intrauterine device/ levonogestrel Intrauterine system (IUS), Depo-Provera(tm

2017 Clinical Trials

128. Maximizing Outcome of Multiple Sclerosis Transplantation

intercourse, (2) consistent use of birth control pills, (3) injectable birth control methods (Depo-provera, Norplant), (4) tubal sterilization or male partner who has undergone vasectomy, (5) placement of an intrauterine device (IUD), or (6) with every act of intercourse, use of diaphragm with contraceptive jelly and/or use of condom with contraceptive foam Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy Forced expiratory volume at one second (FEV1)/ forced

2017 Clinical Trials

129. Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

with subcutaneous insulin by pump at the time of recruitment. Prescription medication regimen stable for > 1 month (except for medications that will not affect the safety of the study and are not expected to affect any outcome of the study, in the judgment of the site PI). Females > 11 years of age must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive

2017 Clinical Trials

130. A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

, e.g., use of oral contraceptives with an additional barrier method (since the study drug may impair the effectiveness of oral contraceptives), double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera, partner vasectomy, total abstinence, and willing to continue the effective contraception method for 30 days after the last dose of study drug; Ability to understand and provide signed informed consent that fulfills Institutional Review Board's

2017 Clinical Trials

131. Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

treatment and for 6 months following the last dose of rucaparib; the following are allowable only: Ongoing use of progesterone-only injectable or implantable contraceptives (eg, Depo Provera, Implanon, Nexplanon) Placement of an intrauterine device or intrauterine system Bilateral tubal occlusion Sterilization, with appropriate post-vasectomy documentation of absence of sperm in ejaculate True, complete (as opposed to periodic) abstinence Exclusion Criteria: Any of the following: Pregnant individuals

2017 Clinical Trials

132. DNA-based Dietary Advice for Adults With Depressive Disorders

prior to the study, and b) they continue on these agents throughout the study. Supplement information will be presented at intake, and the cessation of any such supplements will be required for the participant to continue in screening. Women who are pregnant or breast-feeding; women of childbearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse (for example, intrauterine device, oral contraceptive, implant, Depo-Provera, or barrier devices

2017 Clinical Trials

133. The Effect of Benralizumab on Exercise-induced Bronchoconstriction

; Women of childbearing potential (WOCBP) must use an effective form of birth control (confirmed by the investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device/levonorgestrel Intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch™ or Nuvaring™. WOCBP must agree to use effective method of birth control, as defined above, from enrolment

2017 Clinical Trials

134. Contraceptive use among lactating women in Ganta-Afeshum District, Eastern Tigray, Northern Ethiopia, 2015: a cross sectional study. Full Text available with Trip Pro

delivery was 96.5%. The mode of delivery of the participants was spontaneous, instrumental and caesarean section, 95.5%, 2.0%, and 2.5%, respectively. The magnitude of modern contraceptive (MC) utilization was 68.1% (95% CI: 64.4-71.8). The contraceptive method mix was dominated by Depo-Provera (58.8%) followed by implants (31.8%). Almost all the study participants had at least one antenatal care (ANC) visit (99.7%) during the pregnancy of their index child. Participants who had radio and those who

2017 BMC Pregnancy and Childbirth

135. Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety in Patients With Hypoglycemia After Gastric Surgery

; Current administration of oral or parenteral corticosteroids; Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill/patch I vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide

2017 Clinical Trials

136. Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

contraception (eg, abstinence, double barrier method, oral/implantable/transdermal contraception, Depo-Provera, intrauterine device); a woman is of CBP unless she is premenarchal, is at least 2 years postmenopausal, is without a uterus and/or both ovaries, has had a bilateral tubal ligation, or has undergone the Essure procedure with confirmation of tubal blockage. [Note: If a female is identified as less than 2 years postmenopausal, a serum follicle-stimulating hormone (FSH) determination will be performed

2017 Clinical Trials

137. OT-58 as an Enzyme Replacement Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)

investigational product or investigational medical device within 30 days prior to Screening, or while on study Use or planned use of any injectable drugs containing PEG including medroxyprogesterone (e.g. Depo-Provera) injection within 3 months prior to Screening and while on study Known hypersensitivity to PEG-containing product or any components of OT-58 A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody A history of organ transplantation, chronic immunosuppressive

2017 Clinical Trials

138. Factors associated with contraceptive use in Tigray, North Ethiopia Full Text available with Trip Pro

among 1966 women of reproductive age group (15-49) in 13 districts (3 urban and 10 rural) from May-June 2015. Multistage sampling technique was employed to approach the study participants. Data were analyzed using SPSS version 20. Multiple variable logistic regression analysis was used to identify the effect of independent variables on utilization of contraceptive use.Out of total 1966 women, 1879 (95.6%) have ever heard about family planning. Depo-Provera (depot medroxyprogesterone acetate, or DMPA (...) ) was the most popular contractive method as mentioned by 1757 (93.5%) of the participants. The overall contraceptive prevalence rate among all women was 623 (35.6%) while the contraceptive prevalence rate among married women was 543 (41.0%). Seven-in-ten women had ever used short acting contraceptive. In fact Depo-Provera was the most common type of contraceptive used as mentioned by 402 (64.5%) of the women. The odds of using family planning by married women living in urban areas was two times more than

2017 Reproductive health

139. Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection Full Text available with Trip Pro

Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection Depot medroxyprogesterone acetate (Depo-Provera) has been associated with an increased risk of HIV acquisition. In a longitudinal study, we investigated the impact of Depo-Provera use by healthy women on expression of immune markers for HIV preference and on HIV infection ex vivo at baseline (visit 1), one month (visit 2) and three (...) months (visit 3) after Depo-Provera treatment. We found a significant increase in the frequency and expression of integrin α4β7 on CD4+ T cells at visit 2. Interestingly, Hispanic but not black women exhibited a significant increase in integrin α4β7 cell numbers and expression levels at visit 2, whereas, black but not Hispanic women exhibited a significant change in CCR5 and CD38 expression levels between visit 2 and visit 3. The frequency of terminal effector memory CD4+ T cells decreased

2017 ImmunoHorizons

140. Uptake of long-acting reversible contraceptive devices in Western region of The Gambia Full Text available with Trip Pro

based cross-sectional study of women attending family planning clinic were studied using intervieweradministered questionnaire which included information on socio-demographic factors, reproductive health and contraceptive use of the participants.About 89 % of study participants used long acting reversible contraceptive methods. Of the three commonly available long acting reversible contraceptive methods, Depo Provera was the most commonly used method; 78 of 141 (55.32%); followed by implants (43.3 (...) %) and intrauterine contraceptive (1.42%). Being housewives, with 3-4 living children and having secondary level education were associated with high uptake of LARC.The uptake of long acting reversible contraceptive was high; with Depo Provera as the most commonly used contraceptive method in The Gambia. There seemed to be an increase in the uptake of implants; with intrauterine contraceptive device being the least commonly used method.

2017 African health sciences

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>